Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation
Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N
Record ID 32010000260
English
Authors' objectives:
To determine the clinical effectiveness, safety and cost-effectiveness of etanercept, infliximab and adalimumab for the treatment of active and progressive PsA in patients who have an inadequate response to standard treatment (including DMARD therapy).
Authors' recommendations:
Review found that etanercept, infliximab and adalimumab are efficacious in the treatment of psoriatic arthritis compared with placebo, with beneficial effects on joint symptoms, functional status and skin. Length of follow-up in trials was limited but the evidence to support the use of these biologic agents is convincing, given the size of treatment effect and quality of the data.
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/2053
Year Published:
2011
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antibodies, Monoclonal
- Anti-Inflammatory Agents
- Tumor Necrosis Factor-alpha
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2011 Queen’s Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.